Cantor Fitzgerald Reiterates Overweight on Insmed
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Insmed (NASDAQ:INSM).
September 09, 2024 | 5:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Josh Schimmer has reiterated an Overweight rating on Insmed, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in Insmed's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100